+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Duchenne Muscular Dystrophy - Pipeline Review, H2 2019

  • ID: 4866559
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 330 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Advanced Medical Projects
  • Bioleaders Corp
  • Dyne Therapeutics Inc
  • InnoBioscience LLC
  • Novartis AG
  • ReveraGen BioPharma Inc
  • MORE
Duchenne Muscular Dystrophy - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2019, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 4, 13, 8, 1, 51, 24 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 10 and 2 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Advanced Medical Projects
  • Bioleaders Corp
  • Dyne Therapeutics Inc
  • InnoBioscience LLC
  • Novartis AG
  • ReveraGen BioPharma Inc
  • MORE
Introduction
Duchenne Muscular Dystrophy - Overview
Duchenne Muscular Dystrophy - Therapeutics Development
Duchenne Muscular Dystrophy - Therapeutics Assessment
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
Duchenne Muscular Dystrophy - Drug Profiles
Duchenne Muscular Dystrophy - Dormant Projects
Duchenne Muscular Dystrophy - Discontinued Products
Duchenne Muscular Dystrophy - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Duchenne Muscular Dystrophy, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Universities/Institutes, H2 2019
Table 7: Products under Development by Companies, H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 14: Products under Development by Universities/Institutes, H2 2019
Table 15: Number of Products by Stage and Target, H2 2019
Table 16: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 17: Number of Products by Stage and Mechanism of Action, H2 2019
Table 18: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 19: Number of Products by Stage and Route of Administration, H2 2019
Table 20: Number of Products by Stage and Molecule Type, H2 2019
Table 21: Duchenne Muscular Dystrophy - Pipeline by 4D Molecular Therapeutics Inc, H2 2019
Table 22: Duchenne Muscular Dystrophy - Pipeline by Advanced Medical Projects, H2 2019
Table 23: Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H2 2019
Table 24: Duchenne Muscular Dystrophy - Pipeline by Alpha Anomeric, H2 2019
Table 25: Duchenne Muscular Dystrophy - Pipeline by Anagenesis Biotechnologies SAS, H2 2019
Table 26: Duchenne Muscular Dystrophy - Pipeline by Antisense Therapeutics Ltd, H2 2019
Table 27: Duchenne Muscular Dystrophy - Pipeline by Armgo Pharma Inc, H2 2019
Table 28: Duchenne Muscular Dystrophy - Pipeline by Audentes Therapeutics Inc, H2 2019
Table 29: Duchenne Muscular Dystrophy - Pipeline by AUM LifeTech Inc, H2 2019
Table 30: Duchenne Muscular Dystrophy - Pipeline by Avidity Biosciences LLC, H2 2019
Table 31: Duchenne Muscular Dystrophy - Pipeline by Axolo Pharma Inc, H2 2019
Table 32: Duchenne Muscular Dystrophy - Pipeline by Beech Tree Labs Inc, H2 2019
Table 33: Duchenne Muscular Dystrophy - Pipeline by Biogen Inc, H2 2019
Table 34: Duchenne Muscular Dystrophy - Pipeline by Bioleaders Corp, H2 2019
Table 35: Duchenne Muscular Dystrophy - Pipeline by Biophytis SA, H2 2019
Table 36: Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics Inc, H2 2019
Table 37: Duchenne Muscular Dystrophy - Pipeline by Cardero Therapeutics Inc, H2 2019
Table 38: Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H2 2019
Table 39: Duchenne Muscular Dystrophy - Pipeline by Consortium.AI, H2 2019
Table 40: Duchenne Muscular Dystrophy - Pipeline by Constant Therapeutics LLC, H2 2019
Table 41: Duchenne Muscular Dystrophy - Pipeline by CRISPR Therapeutics AG, H2 2019
Table 42: Duchenne Muscular Dystrophy - Pipeline by Cumberland Pharmaceuticals Inc, H2 2019
Table 43: Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Table 44: Duchenne Muscular Dystrophy - Pipeline by DepYmed Inc, H2 2019
Table 45: Duchenne Muscular Dystrophy - Pipeline by DMD Therapeutics Inc, H2 2019
Table 46: Duchenne Muscular Dystrophy - Pipeline by Dyne Therapeutics Inc, H2 2019
Table 47: Duchenne Muscular Dystrophy - Pipeline by Dystrogen Therapeutics SA, H2 2019
Table 48: Duchenne Muscular Dystrophy - Pipeline by Edgewise Therapeutics, H2 2019
Table 49: Duchenne Muscular Dystrophy - Pipeline by Editas Medicine Inc, H2 2019
Table 50: Duchenne Muscular Dystrophy - Pipeline by Eloxx Pharmaceuticals Inc, H2 2019
Table 51: Duchenne Muscular Dystrophy - Pipeline by Evox Therapeutics Ltd, H2 2019
Table 52: Duchenne Muscular Dystrophy - Pipeline by FibroGen Inc, H2 2019
Table 53: Duchenne Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H2 2019
Table 54: Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H2 2019
Table 55: Duchenne Muscular Dystrophy - Pipeline by Hibernaid Inc, H2 2019
Table 56: Duchenne Muscular Dystrophy - Pipeline by InnoBioscience LLC, H2 2019
Table 57: Duchenne Muscular Dystrophy - Pipeline by Italfarmaco SpA, H2 2019
Table 58: Duchenne Muscular Dystrophy - Pipeline by Keros Therapeutics Inc, H2 2019
Table 59: Duchenne Muscular Dystrophy - Pipeline by LambdaGen Therapeutics, H2 2019
Table 60: Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2019

List of Figures
Figure 1: Number of Products under Development for Duchenne Muscular Dystrophy, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4D Molecular Therapeutics Inc
  • Advanced Medical Projects
  • Akashi Therapeutics Inc
  • Alpha Anomeric
  • Anagenesis Biotechnologies SAS
  • Antisense Therapeutics Ltd
  • Armgo Pharma Inc
  • Audentes Therapeutics Inc
  • AUM LifeTech Inc
  • Avidity Biosciences LLC
  • Axolo Pharma Inc
  • Beech Tree Labs Inc
  • Biogen Inc
  • Bioleaders Corp
  • Biophytis SA
  • Capricor Therapeutics Inc
  • Cardero Therapeutics Inc
  • Catabasis Pharmaceuticals Inc
  • Consortium.AI
  • Constant Therapeutics LLC
  • CRISPR Therapeutics AG
  • Cumberland Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • DepYmed Inc
  • DMD Therapeutics Inc
  • Dyne Therapeutics Inc
  • Dystrogen Therapeutics SA
  • Edgewise Therapeutics
  • Editas Medicine Inc
  • Eloxx Pharmaceuticals Inc
  • Evox Therapeutics Ltd
  • FibroGen Inc
  • Fulcrum Therapeutics Inc
  • Galapagos NV
  • Hibernaid Inc
  • InnoBioscience LLC
  • Italfarmaco SpA
  • Keros Therapeutics Inc
  • LambdaGen Therapeutics
  • Milo Biotechnology LLC
  • Mitobridge Inc
  • Mitochon Pharmaceuticals Inc
  • Myos Inc
  • MyoTherix Inc
  • NicOx SA
  • Nippon Shinyaku Co Ltd
  • Novartis AG
  • NS Pharma Inc
  • OliPass Corporation
  • Oncotelic Inc
  • Pepgen Ltd
  • PeptiDream Inc
  • Pfizer Inc
  • PhaseBio Pharmaceuticals Inc
  • Progenitor Therapeutics Ltd
  • Prothelia Inc
  • PTC Therapeutics Inc
  • RASRx LLC
  • ReveraGen BioPharma Inc
  • Ridgeline Therapeutics LLC
  • Santhera Pharmaceuticals Holding AG
  • Sarcomed AB
  • Sarepta Therapeutics Inc
  • Solid Biosciences Inc
  • SOM Biotech SL
  • Spinalcyte Llc
  • Taiho Pharmaceutical Co Ltd
  • Teijin Pharma Ltd
  • Tivorsan Pharmaceuticals Inc
  • Tolerion Inc
  • Vertex Pharmaceuticals Inc
  • WAVE Life Sciences Ltd
  • Zata Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll